Rapid mRNA LNP Potency Testing for Thermostable Process Development and Point-of-Use Quality Assurance

The project aims to correlate the results of the rapid LNP assay with changes in manufacturing conditions and storage insults such as heating or freeze/thaw cycling to determine which are detectable by the method and with what sensitivity.
Categories
Assays
Process control
Active Immunization Countermeasures

Industry Need

The industry would benefit from more rapid potency testing methods of mRNA LNPs for use in mRNA vaccines, which could be used for point-of-use quality assurance and for testing formulated LNPs at various stages of manufacture and/or storage. 

Approach

This project aims to implement a rapid, reliable electrophoretic assay of critical quality attributes (CQA) of mRNA lipid nanoparticles (LNPs) to be used in mRNA vaccines.  

  • The assay has a less than 10 min readout time and can assay mRNA from LNPs without a separate mRNA release step.  
  • It has the ability to quantitate multiple mRNAs in a single run and can also indicate problems with lipid chemistry.  
  • It can distinguish between folded and unfolded versions of mRNA, as improper mRNA folding may serve as a sentinel of minor mRNA damage.  
  • The assay is compatible with commercial capillary electrophoresis (CE) instrumentation and requires only small volumes to be sampled. 

The team will also subject LNPs to various manufacturing and storage insults and compare CE assay readout with that from state-of-the-art bioassays of mRNA quantity, delivery efficacy, and immunogenicity. 

Impacts

Optimize the assay so it can be used to rapidly quantitate mRNA from LNPs

Distinguish between folded and unfolded versions of mRNA to help detect damage

Method could be used to routinely test formulated LNPs at various stages of their manufacture and/or storage

Value Statement/Outcomes

By implementing a rapid mRNA LNP potency assay with a <10-minute readout, manufacturers can eliminate lengthy release steps and reduce reliance on high-cost stability studies. This approach is projected to cut analytical cycle times by up to 80%, saving of labor hours per product lot and reducing associated costs while accelerating time-to-market for mRNA therapeutics.

Outputs/Deliverables

Development and validation of rapid electrophoretic assays (MCE and MTE) for mRNA LNP potency testing, capable of <10-minute readouts and distinguishing critical quality attributes such as mRNA folding and lipid chemistry.

Implementation of MTE methodology to discriminate mRNA of similar or identical length and apply it for AAV titer analysis.

Technology transfer deliverables, including SOPs, risk-management plans, and integration of MCE/MTE methodology into Eli Lilly’s analytical laboratory workflows.

Posters

Schneider, J., Conference Participant, NMBL-029 Self-Assembly Approaches for Rapid AAV Titer and mRNA Lipid Nanoparticle Quality Assays, NIIMBL National Meeting, Washington, D.C., June 26, 2025.

Presentations

Schneider, J. W., Tynan, K., & Chaudhry, B., Characterization of mRNA lipid nanoparticle quality by surfactant solubilization kinetics, ACS Colloid and Surface Science Symposium, Seattle WA, June 25, 2024.

Additional Project Information (Members Only)

Login to the NIIMBL member portal to access additional project information, including presentations, progress updates, reports, and more.

Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

Project Lead

Carnegie Mellon University

Carnegie Mellon University

Participating Organizations

Eli Lilly and Company

Eli Lilly and Company